| Chemical Structure |
|
| Drug Class | |
| Mechanisms of action | Dopamine - norepinephrine reuptake inhibition (DNRI) Like desoxypipradrol and pipradrol, which also feature a benzhydryl core, 3-Benzhydrylmorpholine likely binds to and inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing reuptake and increasing extracellular concentrations of these monoamines. |
| Monograph | Development: Created by American Home Products in the 1950s. Exhibits stimulant and appetite-suppressant properties As a lipophilic amine, likely crosses the blood-brain barrier, with metabolism possibly involving hepatic cytochrome systems Structural Interest: Among novel morpholine derivatives explored for stimulant or anorectic use in mid - 20th century. Modern Interest: Could serve as a chemical scaffold for designing CNS-active agents It shows stimulant/anorectic properties in concept, its a chemical curiosity of interest primarily to medicinal chemists. |
| Synthesis batch initiated | |Amount acquired for synthesis purposes: 0 mg |Amount acquired for speculative holding: 0 mg Note: These figures reflect total documented acquisitions. Updated manually |
| OrderBook |
Offer
Bid
|
|
Order via(only to Europe, except UK, Denmark, and Austria.) |
|